Abstract
Thoracic manifestations of systemic sclerosis (SSc) are common, occurring in some form in nearly all patients in both limited and diffuse SSc subsets. Most SSc-related mortality is now attributed to end-stage lung disease. All patients with SSc should be screened for the development of ILD and pulmonary hypertension at the time of diagnosis and periodically thereafter. Early diagnosis and appropriate therapy (immunosuppression for ILD and specific vasodilator therapy for pulmonary hypertension) show promise for improved prognosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tashkin DP, Elashoff R, Clements PJ, et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655–66.
Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011;21(12):2455–65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Huggins, J.T., Ravenel, J.G., Silver, R.M. (2014). Lung Involvement in Systemic Sclerosis. In: Mayes, M. (eds) A Visual Guide to Scleroderma and Approach to Treatment. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0980-3_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0980-3_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0979-7
Online ISBN: 978-1-4939-0980-3
eBook Packages: MedicineMedicine (R0)